Metformin Zentiva

Metformin Hydrochloride, the active ingredient in Metformin Zentiva, is a biguanide presented as an oral tablet for oral use. It improves glycemic control by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, and is indicated for adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global distribution. The company adheres to stringent quality standards and offers flexible packaging options to meet diverse market requirements.

Metformin Zentiva is a biguanide oral antidiabetic that acts on glucose metabolism in type 2 diabetes.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired fasting glucose): delays progression to overt diabetes when combined with lifestyle changes. - Metabolic syndrome: assists in weight management and improves insulin sensitivity as part of a comprehensive treatment plan.

Metformin Zentiva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency (long‑term): may develop with prolonged use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Pancreatitis: inflammation of the pancreas. - Hypoglycemia (when combined with other glucose‑lowering agents).

Before initiating Metformin Zentiva, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

- Renal function: evaluate eGFR and avoid use in severe renal impairment. - Hepatic function: monitor liver enzymes, especially in patients with existing liver disease. - Lactic acidosis risk: discontinue before any radiographic contrast studies requiring iodinated agents. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Drug interactions: review concomitant medications that may affect metformin clearance. - Store at room temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformin Zentiva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before and after the procedure. - Cimetidine: can increase metformin plasma concentrations. - Alcohol excess: raises risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (especially thiazides): can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - NSAIDs: may impair renal function, increasing metformin exposure. - Warfarin: occasional alterations in INR; monitor coagulation parameters.